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Sirtuins are a highly conserved class of NADþ -dependent lysine deacylases. The human
isotype Sirt2 has been implicated in the pathogenesis of cancer, inﬂammation and neuro-
degeneration, which makes the modulation of Sirt2 activity a promising strategy for
pharmaceutical intervention. A rational basis for the development of optimized Sirt2
inhibitors is lacking so far. Here we present high-resolution structures of human Sirt2 in
complex with highly selective drug-like inhibitors that show a unique inhibitory mechanism.
Potency and the unprecedented Sirt2 selectivity are based on a ligand-induced structural
rearrangement of the active site unveiling a yet-unexploited binding pocket. Application of the
most potent Sirtuin-rearranging ligand, termed SirReal2, leads to tubulin hyperacetylation in
HeLa cells and induces destabilization of the checkpoint protein BubR1, consistent with Sirt2
inhibition in vivo. Our structural insights into this unique mechanism of selective sirtuin
inhibition provide the basis for further inhibitor development and selective tools for sirtuin
biology.
DOI: 10.1038/ncomms7263 OPEN
1 Institute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstrae 25, 79104 Freiburg im Breisgau, Germany. 2 Institute for Pharmacy,
Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Strae 4, 06120 Halle (Saale), Germany. 3 Institute for Biochemistry and Biotechnology,
Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Strae 3, 06120 Halle (Saale) Germany. 4Department of Genetics, Harvard Medical School,
77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. 5 Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of
Sciences, Magyar Tudo´sok ko¨ru´tja 2, H-1117 Budapest, Hungary. 6Department of Biochemistry, University of Bayreuth, Universita¨tsstrae 30, 95445
Bayreuth, Germany. 7 Institute for Biochemistry and BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg im Breisgau,
Albertstrae 21, 79104 Freiburg im Breisgau, Germany. Correspondence and requests for materials should be addressed to O.E.
(email: einsle@biochemie.uni-freiburg.de) or to M.J. (email: manfred.jung@pharmazie.uni-freiburg.de).
NATURE COMMUNICATIONS | 6:6263 |DOI: 10.1038/ncomms7263 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
N
ADþ -dependent protein deacylases (sirtuins) constitute a
unique class of enzymes that are conserved from bacteria
to humans. Initially recognized as protein deacetylases,
they were recently shown to catalyse further post-translational
modiﬁcations such as demyristoylation1,2, desuccinylation3 or
ADP-ribosylation4. Through a multitude of protein substrates,
they are involved in key cellular processes, including metabolic
sensing, regulation of mitosis and aging. The human isotype
Sirtuin 2 (Sirt2) deacetylates both nuclear and cytoplasmatic
proteins and thereby functions as a major cell cycle regulator5,6,
a determinant of myelination7, a regulator of autophagy8 and a
suppressor of brain inﬂammation9. Generally deemed as a
tumour suppressor10,11 in some types of cancer, Sirt2 was also
shown to adopt a contrary role by promoting tumorigenesis12,13.
In addition, recent reports link Sirt2 to bacteria-induced
reprogramming of host cell gene expression14.
Owing to its multiple regulatory roles, Sirt2 has been
implicated as a potential drug target to combat cancer12,13,
neurodegeneration15,16 and inﬂammation7 but other reports
question the suitability of Sirt2 as a drug target17. The
physiological studies of Sirt2 have so far been hampered by the
lack of potent and isotype-speciﬁc modulators of sirtuin activity.
The biochemistry of sirtuins has been studied extensively in
recent years and three-dimensional structures of the catalytic
domain of several human isotypes provided insight into different
stages of the catalytic cycle18–23. Despite a highly conserved
amino-acid sequence and a high structural similarity of the
catalytic core between the members of the sirtuin family, recent
screening campaigns have identiﬁed several isotype-selective
inhibitors15,24–27. But for only a few of them structural
information is available (Supplementary Fig. 1a) and a strategy
for structure-based optimization of isotype-selective inhibitors
remains mostly elusive. In particular, a structure-derived
rationale for Sirt2-selective inhibition is also lacking so far.
Most recently, the ﬁrst X-ray structure of Sirt2 in complex with a
potent macrocyclic peptidic inhibitor was reported, but this
inhibitor lacked the desired isotype selectivity28 and, due to its
physicochemical properties, might be of limited use for drug
discovery. In this work, we present the ﬁrst crystal structures of
Sirt2 in complex with a potent and Sirt2-selective small-molecule
inhibitor with drug-like properties. The basis for the high
potency and unprecedented isotype selectivity is a ligand-
induced structural rearrangement of the active site, exploiting
an adjacent binding pocket. Along with kinetic studies, the
structures give insight into a unique and isotype-selective
inhibition mechanism. The relevance of the observed
biochemical activity is further supported by cellular studies.
Results
Identiﬁcation and crystallization of SirReal inhibitors. In
search for new sirtuin inhibitors, we screened an internal com-
pound library using an in vitro assay29 based on a ﬂuorophore-
labelled acetyl-lysine derivative for human Sirt1–3. In this
screening campaign, a family of aminothiazoles that we have
termed Sirtuin-rearranging ligands (SirReals) was discovered as
potent, Sirt2-selective inhibitors. Of these, SirReal2 (1) showed
the most promising inhibitory properties (Fig. 1a,b). AGK2 was
used as a reference inhibitor. Under the same assay conditions it
is 38-fold less potent with an IC50 of 15.4±0.7 mM. The activity of
Sirt1 or Sirt3 was not affected at 50 mM. Additional conﬁrmation
of Sirt2-selective in vitro inhibition and binding by SirReal2 was
obtained by using non-labelled peptidic substrates in a high-
performance liquid chromatography (HPLC)-based conversion
assay (Fig. 1c, Supplementary Fig. 1b) and from thermal stability
assays, where the presence of SirReal2 led to increased melting
temperatures due to ligand-induced stabilization of the protein
(Fig. 1d). SirReal2 only inhibits Sirt2 potently with an IC50 value
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Figure 1 | SirReal2 selectively inhibits Sirt2 in a dose-dependent manner. (a) Chemical structure of SirReal2 (1). (b) Representative dose–response curve
for Sirt1–3 and SirReal2 using the substrates ZMAL (Z-Lys(Acetyl)-AMC, Sirt1-2) resp. Fluor-de-Lys (Sirt3). Compared with the peptide-HPLC assay,
SirReal2 was slightly less potent using ZMALwith an IC50 value of 0.4mM. Data are presented as mean±s.d. (n¼ 3). (c) In vitro inhibition data for SirReal2
(Sirt1–3: 100mM; Sirt4–6: 200mM) in an assay using non-labelled acyl-lysine oligopeptide as a substrate (Sirt1–4, acetyl-lysine substrate; Sirt5, succinyl-
lysine substrate; Sirt6, myristoyl-lysine substrate). A solution containing DMSO was used as a negative control, a solution with nicotinamide (NCA,
200mM or 1mM) was used as a positive control. Only the activity of Sirt2 is substantially reduced in the presence of SirReal2. Data are presented as
mean±s.d. (n¼ 2) (d) Representative thermal stability plots for Sirt2 in the presence of SirReal2 (25 mM) and either the cofactor NADþ (5mM) or an
acetyl-lysine H3 peptide (5mM). The presence of NADþ or of an acetyl-lysine peptide substrate enhances the stability of the Sirt2–SirReal2 complex
(n¼ 3). Representative thermal stability plots of Sirt2 in the absence of SirReal2 and in the presence of NADþ or an acetyl-lysine oligopeptide are shown in
Supplementary Fig. 1d. Rel., relative.
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of 140 nM and has very little effect on the activities of Sirt3-5.
Only the activity of Sirt1 (22% inhibition at 100 mM) and Sirt6
(19% inhibition at 200 mM) are slightly affected at higher SirReal2
concentrations, making SirReal2 one of the most selective sirtuin
inhibitors up to date. However, any attempts to identify a
putative-binding site and to rationalize initial structure–activity
relationships by docking to available X-ray structures of
Sirt2 were not successful. We, therefore, proceeded to determine
the structures of Sirt2-inhibitor complexes by protein X-ray
crystallography.
For that, we used a truncated form of Sirt256–356 lacking the
ﬂexible N- and C termini. To validate the suitability of our
expression construct, we also crystallized this truncated form of
Sirt2 in the presence of ADP ribose (ADPR) and the physiological
inhibitor nicotinamide (NCA, Supplementary Fig. 2, structure
termed Sirt2–ADPR–NCA). As the binding mode of these ligands
corresponded to other published sirtuin structures in complex
with NCA30, we concluded that our expression construct was
suitable for the investigation of Sirt2–ligand interactions. Further
thermal stability experiments indicated an additional stabilization
of the Sirt2–SirReal2 complex in the presence of either NADþ or
a peptidic acetyl-lysine substrate (Fig. 1d). These ﬁndings were
the key to a successful crystallization of Sirt2 in complex with
SirReal2 that was only achieved in the presence of either substrate
or cosubstrate.
Overall structure of Sirt2–SirReal2 complexes. We solved the
structure of Sirt2 in complex with SirReal2 and the cosubstrate
NADþ (structure termed Sirt2–SirReal2–NADþ ) as well as in
complex with SirReal2 and an acetyl-lysine peptide derived from
histone H3 (residues 11–17, structure termed Sirt2–SirReal2-H3).
Both Sirt2–SirReal2 crystals belonged to different monoclinic
space groups and contained one monomer per asymmetric unit.
They had the two-domain structure typical for sirtuins-a larger
domain with a Rossmann fold and a smaller zinc-binding domain
that are separated through a large groove that constitutes the
active site (Fig. 2a). The structures are highly similar (root mean
squared deviation, r.m.s.d. (Ca atoms)¼ 0.8 Å) with the main
differences in the cofactor-binding loop and its adjacent residues
(r.m.s.d. (Ca residues 92–115)¼ 1.3 Å). In addition, we observed
the Sirt2-speciﬁc insertion (residues 289–304) that mediates
crystal contacts as was reported for the Sirt2–ADPR complex
(ADPR, PDB-ID 3ZGV19) and apo-Sirt2 (PDB-ID 1J8F, reﬁned
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Figure 2 | SirReal2 functions as a molecular wedge locking Sirt2 in an open conformation. (a) Overlay of Sirt2–SirReal2–NADþ (slate blue) and
Sirt2–SirReal2–H3 (light grey). Both structures are very similar (r.m.s.d. (Ca atoms)¼0.8Å) and feature an open conformation. The active site is indicated
by small grey dots. (b) Superposition of Sirt2–SirReal2–NADþ (slate blue) with Sirt2–apo (PDB-ID 3ZGO, salmon, residues 34–45 are omitted for better
clarity). Both structures feature an open state despite major structural differences in the zinc-binding domain. (c) Superposition of Sirt2–SirReal2–NADþ
(slate blue) with the Sirt2-ADPR complex (PDB-ID 3ZGV, yellow, residues Tyr139-Gly141 of one hinge loop were not deﬁned in the electron density map).
The structures display major conformational differences in the orientation of the zinc-binding domain. While the ADPR complex is in a closed state,
Sirt2–SirReal2–NADþ adopts an open state. (d) Superposition of Sirt2–SirReal2–NADþ with Sirt2 in complex with a macrocyclic peptide inhibitor S2iL5
(PDB-ID 4L3O, green). Similar to the Sirt2–ADPR complex, the Sirt2–S2iL5 complex assumes a closed conformation. While the Rossmann fold domain is
very similar in both structures, major structural differences can be seen at the zinc-binding domain and at the Sirt2-speciﬁc insertion. (e) Close-up view on
the active site using the superposition shown in a. SirReal2 (Sirt2–SirReal2–NADþ , light pink sticks; Sirt2–SirReal–H3, light cyan sticks) occupies the
extended C-site of Sirt2. Binding of SirReal2 neither prevents binding of the acetyl-lysine substrate (light blue sticks) nor the cosubstrate NADþ
(light orange sticks). The cofactor-binding loop of both structures is omitted for clarity.
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3ZGO18,19). The cofactor-binding loop in both Sirt2–SirReal2
complexes adopts a conformation similar to the one observed in
Sirt2 in complex with the product analogue ADPR (PDB-ID
3ZGV).
When compared with the available Sirt2 structures (apo-Sirt2:
PDB-ID 1J8F, 3ZGO; Sirt2-ADPR: PDB-ID 3ZGV; Sirt2–S2iL5
peptide: PDB-ID 4L3O28) the zinc-binding domains in the
Sirt2–SirReal2 structures adopt a conformation similar to the one
in apo-Sirt2 (Fig. 2b–d, Supplementary Fig. 3a–c). On binding of
the acetyl-lysine peptide substrate, the zinc-binding domain
rotates towards the Rossmann fold domain. This has been termed
as the ‘closure’ of the two domains and can be observed in several
other human and bacterial sirtuin structures in complex with an
acetyl-lysine peptide substrate20,21,31. This domain closure
induces the formation of the acetyl-lysine-binding tunnel and
the b-staple motif that mediates the acetyl-lysine peptide
substrate-sirtuin interactions32. Despite the absence of an
acetyl-lysine peptide substrate, the Sirt2–ADPR complexes also
adopt the closed conformation. This is due to the Sirt2-speciﬁc
insertion that acts as a pseudo-substrate in the crystal and
binds to the acetyl-lysine-binding site of a neighbouring Sirt2
molecule.
Despite the ‘open’ conformation of the Sirt2–SirReal2
structures, SirReal2-inhibited Sirt2 adopts a substantially different
structure from the one observed in Sirt2–apo (r.m.s.d.
(Ca atoms)¼ 1.4 Å, Fig. 2b), the complex of Sirt2 and ADPR
(r.m.s.d. (Ca atoms)¼ 1.6 Å, Fig. 2c) and the complex of Sirt2 and
the S2iL5 peptide (r.m.s.d. (Ca atoms)¼ 1.7 Å, Fig. 2d). Our
structures feature a completely new and unexpected Sirt2
conformation, where SirReal2 functions as a ‘molecular wedge’
that traps Sirt2 in the open conformation even in the presence
of an acetyl-lysine peptide substrate. We call this a ‘locked
open’ state.
SirReal2 occupies a yet-unexploited binding pocket. SirReal2
binds to the active site of Sirt2 (Figs 2e and 3) at the interface of
the Rossmann fold domain and the zinc-binding domain, the site
of the deacylation of e-amino groups of lysines. The active site of
Sirt2 has previously been divided into different sites (Fig. 3a). The
A- and B-pocket, respectively, bind the ADPR moiety, whereas
the C-pocket binds the NCA of NADþ . NADþ is able to adopt
different conformations. However, only a kinked conformation
where the NCA moiety of NADþ occupies the C-pocket is
considered productive for catalytic deacylation. The hydrophobic
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Figure 3 | SirReal2 occupies the extended C-site and induces a major rearrangement of Sirt2’s active site. (a) Surface representation of the active site of
apo-Sirt2, designating the individual subsites referred to in the text. (b) Orientation of SirReal2 in the active site of the Sirt2–SirReal2 complexes. The binding
of SirReal2 induces the formation of the yet-unexploited selectivity pocket. (c) Interactions of SirReal2 (light pink) with Sirt2 in complex with the cosubstrate
NADþ (light orange). Interacting residues are represented as sticks (slate blue). Hydrogen bonds are shown as dashed yellow lines. (d) SirReal2 (light pink
sticks, overall B-factor of 32.2Å2) occupies the very hydrophobic extended C-site adjacent to the cosubstrate NADþ (light orange sticks, overall B-factor of
41.8Å2). The surface of Sirt2–SirReal2–NADþ is coloured according to its hydrophobicity (red colour indicating increasing hydrophobicity). The s-weighted
2Fo Fc electron density map is contoured at 1.0 s. A stereo image of d is shown in Supplementary Fig. 4b. s-weighted Fo Fc electron density OMIT
maps for both ligands are shown in Supplementary Fig. 4d. (e) Comparison of the positions of the interacting residues of Sirt2–apo (PDB-ID 3ZGO, salmon),
Sirt2–ADPR (PDB-ID 3ZGV, yellow) and Sirt2–SirReal2–NADþ (slate blue). Residues are shown as sticks. The binding of SirReal2 results in a reorganization
of the side chains of several residues. The most drastic side chain movement was observed for the residues that form the acetyl-lysine substrate channel and
the selectivity pocket. The side chain of Tyr139 of Sirt2–ADPR complex was not deﬁned in the electron density map. The position of the interacting residues
of Sirt2 in complex with the macrocyclic peptide inhibitor S2iL5 are very similar to the ones of Sirt2–ADPR and are therefore not shown.
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acetyl-lysine-binding tunnel is formed by several phenylalanines
and connects the NADþ -binding site to the acetyl-lysine-binding
site. The pocket adjacent to the C-pocket has been termed
extended C-site (EC-site)33.
The aminothiazole SirReal2 occupies this EC-site adjacent to
the C-pocket, which is the physiological site for product
inhibition by the feedback inhibitor NCA30 (Supplementary
Fig. 2). It binds at this highly hydrophobic site in vicinity to the
zinc-binding domain, where it does not interfere with the binding
of NCA or the NCA moiety of NADþ (Fig. 3b–d). The naphthyl
moiety of SirReal2 protrudes into the substrate channel and the
dimethylmercaptopyrimidine substituent (DMP) induces the
formation of a binding pocket beyond the EC-site. This region
is formed by two loops (residues 136–144, residues 188–191) of
the hinge region that connect the Rossmann fold domain with the
zinc-binding domain. We refer to this binding pocket in the
following as the ‘selectivity pocket’. The position of SirReal2 in
the EC-site of Sirt2 is very similar in both structures with either
NADþ or the acetyl-lysine peptide substrate (r.m.s.d. of 0.47Å),
and we will primarily describe the binding of SirReal2 in the
presence of NADþ , as this structure likely represents the
SirReal2-inhibited form of the enzyme. Structural comparison
of the available Sirt2 structures with the Sirt2–SirReal2–H3
complex can be found in Supplementary Fig. 3.
Binding of SirReal2 to the EC-site is mainly driven by
hydrophobic interactions (Fig. 3c,d). The naphthyl moiety of
SirReal2 that protrudes into the acetyl-lysine-binding site is in
van-der-Waals contacts with the NCA moiety of NADþ , Phe131,
Leu134, Ile169, Ile232, Val233 and Phe234. In the selectivity
pocket, the DMP moiety forms p–p-stacking interactions with
Tyr139 and Phe190 in the selectivity pocket that is shaped by
Ile93, Ala135, Leu138, Pro140, Phe143, Leu206 and Ile213. In
addition, Pro94 hydrogen bonds via a structural water molecule
(W40) to the carbonyl-O of SirReal2. Besides its interactions with
the Sirt2 protein, the SirReal2 inhibitor also forms an internal
hydrogen bond between the amide N–H and one of the
pyrimidine nitrogens. This results in a rigid conformation with
ideal complementarity to the active site of Sirt2.
Binding of SirReal2 to Sirt2 rearranges the active site. The
presence of SirReal2 results in a rearrangement of Sirt2’s active
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Figure 4 | SirReal1 selectively inhibits Sirt2 and functions as a molecular wedge to lock Sirt2 in an open conformation. (a) Chemical structure of
SirReal1 (2). (b) Representative thermal stability plots for Sirt2 in the presence of SirReal1 (50 mM) and either the cofactor NADþ (5mM) or an acetyl-
lysine H3 peptide (5mM). The presence of the cosubstrates enhances the stabilization of the Sirt2–SirReal1 complex (n¼ 3). Representative thermal
stability plots of Sirt2 in the absence of SirReal2 and the presence of NADþ or an acetyl-lysine oligopeptide are shown in Supplementary Fig. 1d.
(c) Overlay of Sirt2–SirReal1–OTC (brown) with Sirt2 structures in complex with SirReal2 (Sirt2–SirReal2–H3, light grey; Sirt2–SirReal2–NADþ , slate blue).
All Sirt2–SirReal complexes share a high similarity (r.m.s.d. (Ca atoms)¼0.44Å to Sirt2–SirReal2–H3, 0.59Å to Sirt2–SirReal2–NADþ) and represent the
locked open conformation. The active site is represented as grey dots. (d,e) SirReal1 (light yellow sticks) occupies the extended C-site in a very similar
fashion as observed for SirReal2 (light blue in Sirt2–SirReal2–H3, light pink in Sirt2–SirReal2–NADþ). Differences can be observed for the position of the
side chains of Phe119, Phe235 and the acetyl-lysine peptides. The acetyl-lysine-binding site as well as the selectivity pocket are also the sites of major
conformational changes compared with Sirt2–apo (PBD-ID 3ZGO) and Sirt2-ADPR (PDB-ID 3ZGV, see Fig. 3e). Hydrogen bonds are shown in dashed
yellow lines. The cofactor-binding loop of d is omitted for clarity. A stereo image of the s-weighted 2Fo Fc electron density maps for SirReal1 and the
Ac-Lys-OTC oligopeptide as well as s-weighted Fo Fc electron density OMIT maps of both ligands are shown in Supplementary Fig. 5b,d.
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site. It is more pronounced in comparison with the Sirt2 structure
in complex with ADPR (PDB-ID 3ZGV, Fig. 3e) than with the
structure of Sirt2–apo (PDB-ID 3ZGO, Fig. 3e).
A site of major rearrangement is the selectivity pocket of the
hinge region, where the DMP ring of SirReal2 is bound (Fig. 3e).
Here the loop region from Lys136–Phe143 is substantially shifted
upwards with respect to the Sirt2–apo structure and forms a lid
above the DMP moiety. These residues seem to be more ﬂexible,
indicated by high B-factors, in structures of the closed
conformation such as the Sirt2–ADPR or Sirt2–ADPR–NCA
complexes (Supplementary Fig. 2) than in structures of the open
conformation.
Another site of SirReal2-induced rearrangement is observed in
the acetyl-lysine-binding site. Here the side chains of the residues
forming the highly hydrophobic acetyl-lysine tunnel, Tyr104,
Phe119, Phe131, Phe234 and Phe235 are shifted (Fig. 3e). In
particular, the side chains of Phe235 and Tyr104 that usually cap
the acetyl-lysine are rotated towards the surface of Sirt2.
Surprisingly, this rearrangement does not prevent Sirt2 from
binding its acetyl-lysine peptide substrate, but deacetylation and
the domain closure is blocked effectively.
Kinetic analyses of SirReal-mediated inhibition. In the
course of the investigation SirReal-mediated inhibition, we also
determined the crystal structure of another aminothiazole,
termed SirReal1 (2, Fig. 4a), in complex with Sirt2 and a different
acetyl-lysine peptide substrate. The latter is derived from
ornithine transcarbamoylase (OTC, structure termed Sirt2–
SirReal1–OTC). SirReal1 has a benzyl instead of a naphthyl-
methyl substituent on the aminothiazole and is 26-fold less potent
than SirReal2 in the same in vitro assay, but it retains high Sirt2
selectivity and shows similar behaviour in thermal stability assays
(Supplementary Fig. 1b,c, Fig. 4b). Despite the presence of a
different acetyl-lysine peptide, the structure of Sirt2–SirReal1–
OTC bears a high resemblance to the Sirt2–SirReal2 complexes
(r.m.s.d. (Ca atoms)¼ 0.44 Å to Sirt2–SirReal2–H3, 0.59Å to
Sirt2–SirReal2–NADþ , Fig. 4c). SirReal1 also locks Sirt2 in the
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Figure 5 | SirReal inhibitors suppress Sirt2 activity via a unique mechanism. (a) Superposition of Sirt2–SirReal2–NADþ with ternary sirtuin complexes
(Sir2Tm: PDB-ID 2H4F, aquamarine; Sirt3: PDB-ID 4FVT, raspberry) shows that NADþ in Sirt2–SirReal2–NADþ adopts a very similar kinked conformation
to the one observed in ternary sirtuin complexes. The NCA ribose moiety of NADþ in Sirt2–SirReal2–NADþ shares more resemblance to the position
of NCA ribose of NADþ in 2H4F than to the one in 4FVT. (b) Overlay of Sirt2–SirReal2–H3, Sirt2–SirReal1–OTC with 2H4F of Fig. 4a. The bulky naphthyl
moiety of SirReal2 forces the acetyl-lysine out of its physiological position, which can be seen in the ternary sirtuin complex of Sir2Tm, byB5Å. In this new
position, the Ne-group of the acetyl-lysine of Sirt2–SirReal2–H3 cannot hydrogen bond to the backbone carbonyl-O of the conserved Val232. The less
bulky benzyl moiety of SirReal1 allows a similar acetyl-lysine binding to Sirt2 as observed in the ternary complex of Sir2Tm. However, the presence of
SirReal1 slightly enlarges the distance between the backbone carbonyl-O of Val233 to the Ne of the acetyl-lysine, thus disabling hydrogen bond formation.
(c,d,f,g) Competition analyses of SirReal1/2-mediated inhibition. SirReal2 is a partial non-competitive inhibitor towards NADþ , while SirReal1 functions as
a NADþ -competitive inhibitor. SirReal1 and SirReal2 are both competitive to the acetyl-lysine peptide. Data are presented as mean±s.d. (n¼ 2).
(e) Structure–activity relationships (SAR) for SirReal inhibitors. Only the combination of the bulky naphthyl moiety with the DMP and the non-methylated
amide results in submicromolar Sirt2 inhibition. Inhibition data were determined using the substrate ZMAL (n¼ 3).
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open conformation and shows an almost identical interaction
pattern as observed for SirReal2 (Fig. 4d,e).
To get insights into the inhibition mechanism, we ﬁrst
compared the structures of Sirt2–SirReal complexes with the
available sirtuin structures lacking inhibitors. For the cosubstrate
NADþ , the binding mode does not differ substantially. NADþ
of Sirt2–SirReal2–NADþ also adopts a kinked conformation
with a similar network of hydrophilic and hydrophobic interac-
tions as observed for NADþ or Carba-NADþ in ternary sirtuin
complexes (PDB-ID 2H4F34, Sir2Tm-Ac-Lys-p53-peptide-
NADþ , PDB-ID 4FVT23, Sirt3-Carba-NADþ -Ac-Lys-ACS-
peptide, Fig. 5a). As the main difference, the NCA ribose
moiety of Carba-NADþ is rotated B30 around its glycosidic
bond compared with NADþ in Sirt2–SirReal2–NADþ or
Sir2Tm-Ac-Lys-p53-peptide-NADþ . The binding mode of
NADþ in Sirt2–SirReal2–NADþ therefore shares a higher
resemblance to the conformation of NADþ in the ternary
complex with Sir2Tm.
The acetyl-lysine-binding modes in ternary sirtuin complexes
and Sirt2–SirReal2 structures on the other hand show substantial
differences (Fig. 5b). In uninhibited sirtuin-acetyl-lysine-peptide
structures, the acetyl-lysine-containing peptide binds in the cleft
between the zinc-binding and NADþ -binding domain, respec-
tively, inserting its acetyl-lysine into a hydrophobic tunnel that is
formed by several highly conserved phenylalanines. The binding
of the acetyl-lysine is further stabilized by a hydrogen bond
between the Ne–H of the acetyl-lysine and the backbone
carbonyl-O of a conserved valine. The hydrophobic acetyl-
lysine–binding tunnel is not formed in all Sirt2–SirReal
structures, since Phe235, which usually caps the acetyl-lysine, is
rotated B90 towards the surface. Moreover, the bulky naphthyl
moiety of SirReal2 forces the acetyl-lysine B5Å out of its
physiological position, which can be seen in ternary complexes of
sirtuins (Sir2Tm-Ac-Lys-p53-peptide-NADþ , PDB-ID 2H4F,
Sirt3-Ac-Lys-ACS-peptide-Carba-NADþ , PDB-ID 4FVT, Fig. 5b).
In the Sirt2 complex with SirReal1, the acetyl-lysine-binding
mode is different. The acetyl-lysine adopts an almost physiolo-
gical position, as it is observed in the above-mentioned ternary
sirtuin complexes. However, even in case of SirReal1, the benzyl
moiety of SirReal1 shifts the acetyl-lysine of the OTC peptide
PNVTHYFLRL LH
Sirt2-SirReal2-
NAD+
SirReal2
Sirt1-HM
SirReal2
Sirt3-HM
SirReal2
Phe143
Met296
Phe312
Cys380
Thr171
Leu206
Ile213
Leu134
Leu138
Leu103
Ile118
Ile316
Ile279
Tyr204
Val272
Gly232
Gly265
Consensus . . . :: ***:* . .*:* :*.
Sirt1 244 ---------- ------EDAV KLLQE--CKK IIVLTGAGVS VSCGIPDFRS
Sirt2 65 ---------- ------EGVA RYMQSERCRR VICLVGAGIS TSAGIPDFRS
Sirt3  126 ---------- ------QDVA ELIRARACQR VVVMVGAGIS TPSGIPDFRS
Sirt4 29 IGLFVPASPP LDPEKVKELQ RFITL--SKR LLVMTGAGIS TESGIPDYRS
Sirt5 41 ---------- ------ADFR KFFAK--AKH IVIISGAGVS AESGVPTFRG
Sirt6 35 ---------- ------WELA RLVWQ--SSS VVFHTGAGIS TASGIPDFRG
Consensus . . 
Sirt1 277 RD-GIYARLA VDFPDLPDPQ AMFDIEYFRK DPRPFFKF-- AKEIYPGQFQ
Sirt2 99 PSTGLYDN-L EKYH-LPYPE AIFEISYFKK HPEPFFAL-- AKELYPGQFK
Sirt3 160 PGSGLYSN-L QQYD-LPYPE AIFELPFFFH NPKPFFTL-- AKELYPGNYK
Sirt4 78 EKVGLYAR-T DRRP-IQHGD FVRSAPIR-- --QRYWARNF VGWPQFSSHQ
Sirt5 73 AG-GYWRK-W -------QAQ DLATPLAFAH NPSRVWEFYH YRREVMGSKE
Sirt6 67 PH-GVWTM-E ---------- ---------- --ERGLAP-- KFDTTFESAR
Consensus *. * : . * :**:* *. :*      : : ** :
Sirt1   PSLCHKFIAL SD----KEGK LLRNYTQNID TLEQVAGIQ- –RIIQCHGSF
Sirt2 145
324
206
114
91
PTICHYFMRL LK----DKGL LLRCYTQNID TLERIAGLEQ EDLVEAHGTF
Sirt3 ----DKGL LLRLYTQNID GLERVSGIPA SKLVEAHGTF
Sirt4 122 PNPAHWALST WE----KLGK LYWLVTQNVD ALHTKAGSR- –RLTELHGCM
Sirt5 PNAGHRAIAE CETRLGKQGR RVVVITQNID ELHRKAGTK- –NLLEIHGSL
Sirt6 PTQTHMALVQ LE----RVGL LRFLVSQNVD G
Consensus * *
Sirt1 368 ATASCLI--C KYKVDCE--- ---------- ---------- ----AVRGDI
Sirt2 191 YTSHCVSASC RHEYPLS--- ---------- ---------- ----WMKEKI
Sirt3 252 ASATCTV--C QRPFPGE--- ---------- ---------- ----DIRADV
Sirt4 166 DRVLCLD--C GEQTPRGVLQ ERFQVLNPTW SAEAHGLAPD GDVFLSEEQV
Sirt5 162 FKTRCTS--C GVVAENY--- ---KS--PIC PALSGKGAPE PGTQDASIPV
Sirt6 137 FVEECAK--C KTQYVRDTVV GT-------- ---------- ----MGLKAT
Consensus . :: :: : : :
Sirt1 388 FNQVVPRC-- --PRCPADEP LAIMKPEIVF FGENLPEQFH RAMKYDKDEV
Sirt2 214 FSEVTPKC-- --ED-----C QSLVKPDIVF FGESLPARFF SCMQSDFLKV
Sirt3 273 MADRVPRC-- --PV-----C TGVVKPDIVF FGEPLPQR-F LLHVVDFPMA
Sirt4 214 RSFQVPTC-- --VQ-----C GGHLKPDVVF FGDTVNPDKV DFVHKRVKEA
Sirt5 202 EKLPRCEE-- --AG-----C GGLLRPHVVW FGENLDPAIL EEVDRELAHC
Sirt6 163 GRLCTVAKAR GLRA-----C RGELRDTILD WEDSLPDRDL ALADEASRNA
Consensus *  : :*:* : . : .*
Sirt1 434 DLLIVIGSSL KVRPVALIPS SIP-HEVPQI LINREPLP-- ----------
Sirt2 255 DLLLVMGTSL QVQPFASLIS KAP-LSTPRL LINKEKAGQS DPFLGMIMGL
Sirt3 313 DLLLILGTSL EVEPFASLTE AVR-SSVPRL LINRDLVG-- ----------
Sirt4 255 DSLLVVGSSL QVYSGYRFIL TAWEKKLPIA ILNIGPTR-- ----------
Sirt5 243 DLCLVVGTSS VVYPAAMFAP QVAARGVPVA EFNTETTP-- ----------
Sirt6 208 DLSITLGTSL QIRPSGNLPL ATKRRGGRLV IVNLQPTK-- ----------
Consensus .   .
Sirt1 471 ----HL---- -HFDVELLGD CDVIINELCH RL-GGEYA
Sirt2 305 GGGMDFDSKK AYRDVAWLGE CDQGCLALAE LL-GWKKE
Sirt3 350 ----PLAWHP RSRDVAQLGD VVHGVESLVE LL-GWTEE
Sirt4 293 ----SD---- DLACLKLNSR CGELLP---- ---LIDPC
Sirt5 281 ----AT---- NRFRFHFQGP CGTTLPEALA -CHENETV
Sirt6 246 ----HD---- RHADLRIHGY VDEVMTRLMK HL-GLEIP
Figure 6 | SirReal2 selectively inhibits Sirt2 via a Sirt2-speciﬁc amino acid network. (a) Structural sequence alignment of the Sirt1–6 deacylase domain.
The residues that presumably interact with SirReal2 are highlighted in yellow if they are equivalent to the residues of Sirt2. If they differ from the residues of
Sirt2, they are highlighted in red. The structural sequence alignment was generated using T-Coffee35 and slightly modiﬁed. (b–d) Surface representation of
the binding pockets of SirReal2 in Sirt2–SirReal2–NADþ and in the homology models of Sirt1 (Sirt1-HM) and Sirt3 (Sirt3-HM). The residues that differ in
the three isotypes are represented as sticks (Sirt2, slate blue; Sirt1, brown; Sirt3, turquoise). SirReal2 is shown as light pink sticks (Sirt2–SirReal2–NADþ),
lime sticks (Sirt1-HM) and olive sticks (Sirt3-HM). Despite the highly conserved active site, the binding pockets appear in very different shapes due to
differences in the amino acid sequence. In case of Sirt1 the amino acids that contribute to an unfavourable binding of SirReal2 are Ile279, Met296, Phe312,
Ile316 and Cys380. In the case of Sirt3, the amino acids are Tyr204, Gly232, Gly265 and Val272.
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towards His187, weakening the formation of the hydrogen bond
between the Ne–H of the acetyl-lysine and the backbone
carbonyl-O of the conserved valine (distance between carbonyl-
O of valine and Ne-KAc: 3.2 Å in Sirt2–SirReal1–OTC, 2.5–2.7 Å
in ternary complexes).
To investigate the SirReal-mediated inhibition kinetics, we
performed competition analyses for SirReal1 and SirReal2
(Fig. 5c,d,f and g). SirReal2 is partially non-competitive and
SirReal1 is competitive towards NADþ (Fig. 5c,f). Both SirReal
inhibitors also exhibit acetyl-lysine competition with inhibition
constants of 0.22 mM for SirReal2 and 3.33 mM for SirReal1
(Fig. 5d,g). This is in line with the protrusion into the
acetyl-lysine-binding site that was seen in the crystal structures.
However, despite competition towards acetyl-lysine substrates or
the cosubstrate NADþ , the presence of SirReal1/2 inhibitors does
not disable Sirt2 to bind its substrates.
For further exploration of the SirReal-mediated Sirt2 inhibi-
tion, we synthesized several SirReal derivatives (SirReal3–6,
Supplementary Fig. 5, Supplementary Notes) and determined
their inhibitory potencies (Fig. 5e). Only the combined presence
of the naphthyl substituent with the DMP moiety and the non-
methylated amide leads to a submicromolar Sirt2 inhibition. The
substitution of the DMP moiety with a dimethylmercaptophenyl
substituent or the methylation of the amide-nitrogen results in a
signiﬁcant loss of inhibition (4100-fold). This suggests that the
formation of the intramolecular hydrogen bond and the resulting
structural rigidity of Sirt2-bound SirReal2 are indispensable for
potent Sirt2 inhibition.
Structural aspects of isotype-selective inhibition. One striking
feature of the SirReal2-mediated inhibition is its isotype
selectivity. SirReal2 inhibits Sirt241,000-fold more potently than
Sirt1, Sirt3, Sirt4, Sirt5 and Sirt6 and it is therefore one of the
most selective sirtuin inhibitors known to date.
To analyse the basis of this high isotype selectivity, we created a
structural sequence alignment of the deacylase domain of Sirt1–6
and compared the crystal structure of the Sirt2–SirReal2 complex
with available crystal structures of sirtuins in their open
conformation (Fig. 6a, Supplementary Fig. 7a,b)35. Assuming
that SirReal2 binds to the other sirtuin isotypes in a similar
fashion as observed for Sirt2, Sirt4–6 exhibit major differences in
their amino acid sequence. The structural differences are also very
pronounced (Supplementary Fig. 7a) rationalizing the observed
lacking in vitro inhibition of Sirt4–6 by SirReal2. Sirt1 and Sirt3,
on the other hand, are phylogenetically more closely related to
Sirt2 and show only minor sequence variations36. Their
conformation is more similar to the Sirt2–SirReal2–NADþ
complex than to the conformation of the isotypes Sirt5/6
(Supplementary Fig. 7b). But they still show major structural
differences (r.m.s.d. (Ca atoms)¼ 1.6 Å). As it was not possible to
dock SirReal2 in any of the available Sirt1 and Sirt3 X-ray crystal
structures (Supplementary Methods), we wanted to probe
whether Sirt1 and Sirt3 were able to adopt a similar
conformation as observed in the Sirt2–SirReal2 structures that
would allow binding of SirReal2. This would enable us to see
whether the minor sequence variations within the deacylase
domain of Sirt1–3 would have an inﬂuence on SirReal2 binding.
Therefore, we generated homology models of Sirt1 (Sirt1-HM)
and Sirt3 (Sirt3-HM) based on our Sirt2–SirReal2 structures
(Supplementary Methods). Stereochemical analyses as well as
molecular dynamics simulations indicated high-quality model
structures, and it was indeed possible to dock SirReal2 into these
homology models (Supplementary Fig. 7c–h). However, the
docking poses of SirReal2 in Sirt1-HM and Sirt3-HM gave less
favourable docking scores compared with the requisite scores for
the docking poses of SirReal2 in Sirt2–SirReal2 structures. Here
the position and the conformation of SirReal2 were correctly
predicted (Fig. 6b). In case of Sirt1, residues Leu103, Ile118,
Leu134, Leu138 and Leu206 of Sirt2 are substituted with Ile279,
Met296, Phe312, Ile316 and Cys380 (Fig. 6c). Cys380 gives the
hypothetical selectivity pocket of SirReal2 in Sirt1-HM a very
different shape and changes its surface characteristics. The bulky
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Figure 7 | SirReal2 inhibits Sirt2 in vivo. (a) Acetylation level of the microtubule network (red) in the presence or absence of SirReal2 at a concentration of
20mM. Treatment with SirReal2 leads to hyperacetylation of the microtubule network in a similar manner as observed for the Sirt2 inhibitor AGK2.
Treatment with SirReal6 on the other hand results in no substantial change of acetylation level. The scale bar represents 5 mm (n¼4). (b) Abundance of
BubR1 after incubation with SirReal2 (n¼ 3). (c) SirReal2 does not alter p53-Lys382-acetylation after ultraviolet damage (n¼ 3). Raw immunoﬂuorescent
images and uncropped blots are shown in the Supplementary Figs 8–10.
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Phe312 and Ile316 as well as Met296 and Ile279 also tighten the
EC-site, resulting in an unfavourable orientation of the
aminothiazole and naphthyl moieties in possible docking poses.
In the case of Sirt3, the differences are mainly located at the
selectivity pocket. Here Phe143, Thr171, Leu206 and Ile213 of
Sirt2 are substituted by Tyr204, Gly232, Gly265 and Val272
(Fig. 6d). The less bulky Gly232, Gly265, Val272 of Sirt3 form a
much wider and also more solvent-accessible selectivity pocket as
compared with the Sirt2–SirReal2 structures. In contrast to the
SirReal2-binding pockets of the homology models of Sirt1 and
Sirt3, SirReal2 bound to Sirt2 can adopt a conformation that is in
almost perfect complementarity with the protein, which is
stabilized by the intramolecular hydrogen bond between the
DMP substituent and the amide. This is not possible in Sirt1 and
Sirt3 and also rationalizes the observed isotype selectivity.
In vivo inhibition of Sirt2. To validate that SirReal2 could be
used as a tool to investigate the effects of Sirt2 inhibition in a
cellular setting, we incubated HeLa cells with SirReal2 at various
concentrations and determined the level of a-tubulin acetylation
(Supplementary Fig. 8a,b). Incubation with SirReal2, but not with
SirReal6, resulted in a signiﬁcant increase of a-tubulin acetylation
consistent with an in vivo inhibition of Sirt2 as shown pre-
viously37. These changes are not as pronounced when compared
with the changes induced by the inhibition of the other main
tubulin deacetylase KDAC6 (refs 38,39). KDAC6 activity is not
affected in vitro in the presence of SirReal2 (Supplementary
Fig. 8c). To verify the observations from the western blot data,
we also visualized the acetylation level by means of
immunoﬂuorescence microscopy. Again, the incubation with
SirReal2 resulted in a partial increase of the acetylation of
the microtubule network similar to the effects observed after
treatment with the Sirt2-inhibitor AGK2 (Fig. 7a, Supplementary
Fig. 9)39,40. SirReal6, on the other hand, does not alter
microtubule acetylation. In addition, we analysed another Sirt2
target. Recently, we reported that the stability of spindle assembly
checkpoint protein BubR1 is under control of Sirt2 (ref. 41).
A decline in BubR1 over time has been linked to mammalian
aging42. Deacetylation of Lys668 of BubR1 by Sirt2 inhibits the
ubiquitination of BubR1 and its designation to the proteasome.
Therefore, the abundance of BubR1 can be used as a functional
measure for in vivo Sirt2 inhibition. Incubation with SirReal2
indeed signiﬁcantly resulted in a dose-dependent depletion
of BubR1, whereas SirReal5/6 did not inﬂuence BubR1
concentrations (Fig. 7b, Supplementary Fig. 8d,e). We also
found that SirReal2 treatment did not alter cell cycle
distribution, ruling out that the effect on BubR1 was indirect
through induction of cell cycle changes (Supplementary Fig. 8f).
To determine if SirReal2 selectively inhibits Sirt2 in vivo, we
assessed p53 acetylation following genotoxic stress (Fig. 7c,
Supplementary Fig. 10a). Acetylation of p53 occurs in response to
ultraviolet exposure to cells43 and this acetylation is regulated, in
part, by the isotype Sirt1 (refs 44,45). On exposure to ultraviolet
light, we detected an increase in acetylation of p53, which was
further increased on treatment with the pan-sirtuin inhibitor
Table 1 | Data collection and reﬁnement statistics.
Sirt2–SirReal1–OTC* Sirt2–SirReal2–H3* Sirt2–SirReal2–NADþ *
Data collection
Space group P21 P21 I2
Cell dimensions (Å)
a, b, c (Å) 36.21, 73.75, 55.86 35.99, 73.30, 55.29 83.7, 54.51, 96.69
a, b, g () 90, 94.71, 90 90, 95.23, 90 90, 114.8, 90
Resolution (Å)w 44.43–1.45 (1.48–1.45) 44.02–1.42 (1.44–1.42) 48.28–1.88 (1.92–1.88)
Rmerge 0.126 (1.009) 0.060 (0.922) 0.068 (1.351)
Rpim 0.054 (0.471) 0.035 (0.546) 0.029 (0.583)
I/sI 9.2 (1.7) 11.9 (1.5) 19.3 (1.5)
Completeness (%) 99.9 (99.9) 99.6 (99.6) 100 (100)
CC1/2 0.995 (0.549) 0.999 (0.534) 0.999 (0.585)
Redundancy 6.5 (6.2) 3.7 (3.8) 6.6 (6.4)
Reﬁnement
Resolution (Å) 44.43–1.45 44.02–1.42 48.28–1.88
No. of reﬂections 334,389 (16,809) 199,366 (10,043) 213,173 (12,962)
Rwork/Rfree (%) 26.0/28.2 18.1/18.8 20.2/24.7
No. of atoms
Protein 2,251 2,406 2,350
SirReal inhibitor 25 29 29
Ac-Lys peptide/NADþ 32 12 44
Zn2þ 1 1 1
Water 156 242 99
B-factors (Å2)
Protein 17.3 21.1 38.4
SirReal inhibitor 27.0 25.1 32.2
Ac-Lys peptide/NADþ 29.8 48.3 41.8
Zn2þ 11.7 14.8 30.7
Water 20.5 27.0 36.0
r.m.s. deviations
Bond lengths (Å) 0.012 0.008 0.014
Bond angles () 1.58 1.33 1.65
Ac-Lys, acetyl-lysine; r.m.s., root mean squared.
*Each data set was obtained from one single crystal. Sirt2–SirReal1–OTC and Sirt2–SirReal2–H3 were collected at 1.0Å at the Swiss Light Source (Villigen, Switzerland), Sirt2–SirReal2–NADþ was
collected with an in-house X-ray source at 1.5418Å.
wValues in parentheses are for highest-resolution shell.
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NCA. However, we did not observe an increase in acetylation of
p53 following treatment with SirReal2/5/6. Similarly, we also
tested if SirReal2 could inhibit Sirt3 in cells by assessing
mitochondrial protein acetylation. Sirt3 has previously been
demonstrated to regulate global mitochondrial protein
acetylation46. Following treatment with SirReal2 or NCA as a
positive control, we puriﬁed mitochondria and assessed protein
acetylation by western blotting. We found that treatment with
NCA leads to an increase in the acetylation of mitochondrial
proteins, whereas treatment with SirReal2 did not, suggesting that
SirReal2 is unable to regulate Sirt3 activity in cells
(Supplementary Fig. 10b). These results conﬁrm the in vitro
observations and indicate that SirReal2 has a strong speciﬁcity
towards Sirt2 in vivo when compared with the other members of
Class-I sirtuins Sirt1 and Sirt3.
Discussion
There are many indications that sirtuins play an important role in
neurodegeneration, cancer, bacterial infections and inﬂammation
and that a modulation of Sirt2 activity could be a new strategy for
pharmaceutical intervention. However, the physiological func-
tions of Sirt2 are far from being completely understood and
conclusive evidence for the suitability of Sirt2 as a pharmaceutical
target is, at least in some cases, missing. To further explore Sirt2
function in a cellular environment, there is a deﬁnite need for
selective and potent Sirt2 modulators.
So far, most sirtuin modulators lack either potency, selectivity
or drug-like physicochemical properties. Recent screening
campaigns have identiﬁed several potent and/or selective
inhibitors15,24–26; however, with the exception of the
macrocyclic peptide S2iL5, it is not clear how these inhibitors
bind to Sirt2. And although several X-ray structures of sirtuins in
complex with inhibitors have been reported lately28,33,47–51, these
structures do little to reveal a rationale for a Sirt2-selective
inhibition.
With the identiﬁcation of the SirReal inhibitors, we establish
the structural basis for Sirt2-selective inhibition and report a new
potent Sirt2-selective inhibitor scaffold. As noted above, the
intramolecular hydrogen bond between the amide of the
aminothiazole and a nitrogen atom of the DMP moiety gives
the inhibitor a rigid form that can act as a molecular wedge
locking the enzyme conformation with subsequent Sirt2 inhibi-
tion. Not only essential for the potency, the intramolecular bond
also seems to play an important role for the compound’s Sirt2
selectivity, as it can only be formed when bound in perfect
complementarity to the active site of Sirt2. This seems not to be
possible if bound to Sirt1 or Sirt3.
Another important aspect alongside the internal hydrogen
bond of SirReal-mediated Sirt2 inhibition is the exploitation of
the selectivity pocket by SirReal inhibitors. The only other
isotype-selective sirtuin inhibitors with known structures,
CHIC-35 (Sirt1-selective)48, EX-527 (Sirt1-selective)33 and
SRT1720 (Sirt3-selective)49 either bind to the EC-site and/or to
the acetyl-lysine-binding site but neither the indole inhibitors nor
SRT1720 or any of the inhibitors whose binding modes have been
elucidated by means of X-ray crystallography occupy the
selectivity pocket (Fig. 6). This pocket is formed by two loops
that connect the Rossmann fold domain with the smaller zinc-
binding domain. The residues that form this pocket signiﬁcantly
differ within the sirtuin family and targeting this pocket may
present a new strategy for selective sirtuin inhibitor design. These
particular ﬁndings would not have been discovered with the use
of computational methods and the available Sirt2 structures.
In conclusion, with the identiﬁcation of SirReal2, we provide
an isotype-selective drug-like inhibitor with optimized potency
and physicochemical properties in comparison with previously
published Sirt2 inhibitors (Supplementary Table 1). We estab-
lished valuable structural insights into selective Sirt2 inhibition
and show that SirReal2 inhibits Sirt2 in vivo without affecting the
activity of the other Class-I sirtuins Sirt1 and Sirt3. The observed
selectivity towards Sirt3 may, in part, stem from a lack of
penetration into the mitochondria but the cellular net result is as
desired. SirReal2 may therefore be used for further cellular studies
to probe Sirt2 biology. Our ﬁndings may constitute the basis for
further selective sirtuin inhibitor development and provide a new
tool for sirtuin biology.
Methods
Cloning. The gene sequences coding for human Sirt256–356 (Uniprot: Q8IXJ6) or
human Sirt3118–395 (Uniprot: Q9NTG) were cloned in a modiﬁed pET15b vector
that contained His10-Tag instead of a His6-Tag and a cleavage site for TEV protease
instead of one for thrombin.
Protein expression and puriﬁcation. Human Sirt1133–747 (Uniprot: Q96EB6),
human Sirt225–389, human Sirt3101–399, human Sirt534–302 (Uniprot: Q9NXA8)
and human Sirt613–308 (Uniprot: Q8N6T7) were puriﬁed as described before47,52,53.
Human Sirt425–314 (Uniprot: Q9Y6E7) was expressed and puriﬁed as described
before54 with the exception that autoinduction with 0.2% (w/v) lactose in TB media
was used for expression.
Sirt256–356 and Sirt3118–395 were expressed in E. coli strain
BL21(DE3)Codonplus RIPL cells overnight at 18 C. Overexpression was induced
with isopropyl-b-D-thiogalactoside (0.1mM) at an OD600 of 0.6. Cells were
harvested, resuspended in lysis buffer (Sirt256–356: 50mM Tris/HCl, 500mM NaCl,
5% (v/v) glycerol, 5mM b-mercaptoethanol, pH 8.0; Sirt3118–395: 50mM HEPES,
500mM NaCl, 5% (v/v) glycerol, 5mM b-mercaptoethanol, pH 7.5) and lysed
using a microﬂuidizer (Microﬂuidics). After the removal of cell debris, the
supernatant was applied to a HisTrapFF 5ml column (GE Healthcare), washed
intensively before TEV protease (excess) was applied directly on the column. After
an overnight digestion at 4 C, the digested protein was eluted with lysis buffer,
concentrated and further puriﬁed using a Superdex S75 26/60 gel ﬁltration column
(Sirt256–356: 25mM Tris/HCl, 150mM NaCl, pH 8.0; Sirt3118–395: 25mM
HEPES, 200mM NaCl, 5% (v/v) glycerol, 5mM b-mercaptoethanol, pH 7.5).
Sirtuin-containing fractions were collected and concentrated to 20mgml 1. All
puriﬁcation steps were monitored using SDS-polyacrylamide gel electrophoresis
(SDS–PAGE). Protein concentration was determined by the Bradford assay (Roth).
In vitro sirtuin assay. Initial screens were conducted with a high-throughput
ﬂuorescence-based assay using the substrate ZMAL (Z-Lys(Acetyl)-AMC) that was
synthesized according to published procedures29. For this human Sirt1133–747,
human Sirt225–389, human Sirt3101–399 or Sirt3118–395 were mixed with assay buffer
(50mM Tris/HCl, 137mM NaCl, 2.7mM KCl, 1mM MgCl2, pH 8.0), b-NADþ
(ﬁnal assay concentration 500mM), the substrate ZMAL (ﬁnal assay concentration
10.5 mM from a 12.6mM stock solution in DMSO) and the respective inhibitor in
DMSO at various concentrations or DMSO as a control (ﬁnal DMSO
concentration 5–20% (v/v)). The mixture was incubated at 37 C for 4 h, with
agitation at 150 r.p.m. Deacetylation was then stopped by the addition of a solution
containing NCA and trypsin (50mM Tris/HCl, 100mM NaCl, 6.7% (v/v) DMSO,
trypsin 5.5 U ml 1, 8mM NCA, pH 8.0, 60 ml) and the mixture was then incubated
for tryptic digestion of the deacetylated product to release the ﬂuorophor (20min,
37 C, 150 r.p.m.). Then the ﬂuorescence intensity was measured in a microplate
reader (BMG Polarstar, lex 390 nm, lem 460 nm). The amount of inhibition was
determined with respect to the mixture with only DMSO. IC50 values were
determined with Graphpad Prism software using a non-linear regression to ﬁt the
dose–response curve. SirReal1 and SirReal2 were also tested for Sirt1–3 inhibition
with a non-labelled acetyl-lysine peptide substrate (based on a-tubulin with two
additional tryptophans (residues 36–44, H-PSDK(Acetyl)TIGGWW-NH2, 10 mM,
Supplementary Methods). SirReal2 was also tested for Sirt5–6 inhibition with non-
labelled acyl-lysine peptide substrates (Sirt5: Benzoyl-GVLK(Succinyl)EYGV-NH2,
10 mM; Sirt6: Ac-EALPKK(Myristoyl)TGG-NH2, 10 mM) The substrate was
incubated (10min,B0.5 mM Sirt1/2/3/5/6, 500mM b-NADþ , 5–20% (v/v) DMSO,
50mM Tris/HCl, 137mM NaCl, 2.7mM KCl, 1mM MgCl2, pH 8.0), stopped by
the addition of triﬂuoroacetic acid (TFA, 10% (v/v), ﬁnal concentration 1% (v/v)).
The components of the stopped reaction mixture were separated by HPLC (Agilent
1100, Phenomenex reversed phase column Kinetex RP18 2.7 mm, 50 3mm) using
a linear gradient of acetonitrile (20–60% (v/v) acetonitrile, 0.1% (v/v) TFA,
0.6mlmin 1). Peaks of acetylated and deacetylated substrate were quantiﬁed by
absorption at 280 nm. Sirt4-dependent deacetylation reactions were performed
with an acetylated Nnt397-peptide (H-NITKLLK(Acetyl)AISPDK-NH2, 250 mM,
GL Biochem., in 50mM Tris/HCl, 150mM NaCl, pH 7.5). Samples were taken
between 0 and 45min and reactions were stopped by mixing 1:1 with 0.5% (v/v)
TFA. The samples were then diluted to a peptide concentration of 5 mM with 0.1%
(v/v) formic acid and analysed on an EASY-nLCII connected to a LTQ mass
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spectrometer (Thermo Fisher Scientiﬁc). Peptides were separated by a linear
gradient of acetonitrile (0–100% (v/v), 0.1% (v/v) TFA, 300 nlmin 1) on a reprosil
C18 reversed phase column. Peak areas of acetylated and deacetylated peptides
were extracted using Skyline55. A solution with DMSO was used as a negative
control while a solution with the physiological inhibitor NCA served as a positive
control (Fig. 1c). Owing to the lack of a suitable screening assay for human Sirt7,
we focused our studies on isotypes Sirt1–6. Fluor-de-Lys assays (Enzo Life
Sciences) were conducted according to the manual using the HDAC8 Fluor-de-Lys
deacetylase substrate (BML-KI178-0005).
Protein crystallization. All crystallization trials were performed in 96-well plates
(Intelli-Plate 96-3 Low Proﬁle, Art Robbins Instruments) using an Oryx nano
pipetting robot (Douglas Instruments). Reservoir solutions were precooled to 4 C
and screens were then pipetted at 20 C.
For co-crystallization experiments with SirReal1 and SirReal2, a solution of the
truncated Sirt256–356 (20mgml 1 ﬁnal concentration) was preincubated with a
saturated aminothiazole solution (100mM stock solution in DMSO, 1–2% (v/v)
DMSO ﬁnal concentration) in the presence of H3 peptide (100mM stock solution
in 25mM HEPES, 200mM NaCl, 5% (v/v) glycerol, pH 7.5, 2mM ﬁnal
concentration, derived from acetylated Histone H3 (residues 11–17), Peptide
Specialty Laboratories), acetylated OTC oligopeptide (100mM stock solution in
DMSO, 2mM ﬁnal concentration, derived from ornithine transcarbamoylase
(residues 83–92), Peptide Specialty Laboratories) or b-NADþ (Sigma-Aldrich,
100mM stock solution in 25mM Tris/HCl, 150mM NaCl, pH 8.0, 10mM ﬁnal
concentration) for 60min at 4 C, centrifuged (4 C, 10min, 16,100 g) and
crystallized. Sirt2–SirReal1–OTC–peptide complex crystallized in 25% (w/v)
polyethylene glycol (PEG) 3,350 and 0.1M Bis–Tris buffer at pH of 6.5 and 4 C,
Sirt2–SirReal2–H3–peptide complex crystallized in 2.8M (NH4)2SO4 and 0.1M
Tris/HCl buffer at pH 9.0 and 4 C. For both conditions, a protein solution to
reservoir solution ratio of 1:3 was used. The Sirt2–SirReal2–NADþ complex
crystallized in 0.1M KSCN, 30% (w/v) PEG MME 2,000 at 4 C with a protein
solution to reservoir solution ratio of 3:1. The crystals were mounted in nylon loops
and if required, cryoprotected by the addition of 20% (v/v) of glycerol before ﬂash
cooling in liquid nitrogen.
Crystals of Sirt2 in complex with ADPR (13mgml 1 ﬁnal concentration,
20mM ADPR, 1M stock solution in 1M Tris/HCl buffer at pH 9.0) were obtained
using 18% (w/v) PEG 10,000 and 0.1M Bis–Tris buffer at pH 5.75 and 20 C. The
crystals formed after 1 day and were then soaked in a buffer containing 18% (w/v)
PEG 10,000, 0.1M Bis–Tris buffer at pH 5.75, 200mM NCA for 30min. They were
then mounted in nylon loops after addition of glycerol to a ﬁnal concentration of
20% (v/v) before ﬂash cooling in liquid nitrogen.
Data collection and processing. Data were collected at beamline X06SA (Sirt2–
SirReal2–H3 complex) or X06DA (Sirt2–SirReal1–OTC complex, Sirt2–ADPR–
NCA complex) with Pilatus detectors (Dectris) at the Swiss Light Source (Villigen,
Switzerland). All experiments were carried out at 100 K with oscillations of 0.25 or
0.5 at an X-ray wavelength of 1.0 Å. The Sirt2–SirReal2–NADþ complex was
determined from data collected on a MicroMax 007HF rotating anode X-ray
generator (Rigaku) at an X-ray wavelength of 1.5418Å, equipped with a mar345
image plate detector (Mar Research). All data sets were processed with Imosﬂm56
or XDS57 and scaled based on the CC* criterion58 using Aimless56.
Structure solution and reﬁnement. All structures were solved by molecular
replacement using either MOLREP59 or PHASER60 with a monomer of
Sirt2–ADPR (PDB-ID 3ZGV)19 or the initial Sirt2-aminothiazole-structure
(Sirt2–SirReal2–H3) as a search model. Model building was carried out using
Coot61 and the structure was reﬁned with REFMAC5 (ref. 62). Ligands were
generated using the Grade Web Server (Global Phasing Ltd., Cambridge). All
structures were validated using the Molprobity server63.
Sirt2–SirReal1–OTC was reﬁned to a ﬁnal Rwork of 26.0% and Rfree of 28.2%
with 98% of all amino acids of the reﬁned model found in the most favored regions
of the Ramachandran plot. Sirt2–SirReal2–H3 was reﬁned to a ﬁnal Rwork of 18.1%
and Rfree of 18.8% with 98% of all residues falling into the most-favoured region of
the Ramachandran plot. The Sirt2–SirReal2–NADþ complex was reﬁned to a ﬁnal
Rwork of 20.2% and Rfree of 24.7% with 97% of all residues in the most-favoured
Ramachandran plot regions. Finally, the Sirt2–ADPR–NCA complex was reﬁned to
a ﬁnal Rwork of 21.1% and Rfree of 23.9% with 98% of all residues in the most
favored Ramachandran plot regions. All structures do not have Ramachandran
outliers. Further data collection and reﬁnement statistics are found in Table 1
(Sirt2–SirReal1–OTC, Sirt2–SirReal2–H3, Sirt2–SirReal2–NADþ ) and in
Supplementary Table 2 (Sirt2–ADPR–NCA).
Most of the residues of all new structures are well deﬁned in the electron density
maps except for some parts of the ﬂexible cofactor-binding loop (residues 96–120,
Sirt2–SirReal2–NADþ , Sirt2–SirReal2–H3, Sirt2–SirReal1–OTC) and parts of
the Sirt2-speciﬁc insertion loop (residues 295–305, Sirt2–SirReal2–NADþ ,
Sirt2–SirReal2–H3, Sirt2–SirReal1–OTC). The weak density for NADþ in the
Sirt2–SirReal2–NADþ complex may also be due to partial hydrolysis of NADþ
and the formation of different conformers. The visible amino-terminal histidine
and methionine visible in the Sirt2–ADPR–NCA complex and Sirt2–SirReal2–
NADþ complex structures originate from the NdeI restriction site of the modiﬁed
pET15b vector. s-weighted Fo Fc electron density OMIT maps were generated
with the Phenix suite64. Images were prepared with Pymol (The Pymol Molecular
Graphics System, Version 1.6, Schro¨dinger, LLC), r.m.s.d. values were calculated
with SUPERPOSE65 and the surface of the binding pockets was generated using
HOLLOW66. The two-dimensional representation of the interactions of NCA with
Sirt2 were generated with LigPlotþ 67.
Determination of kinetic parameters for SirReal1/2. For SirReal-inhibition
kinetics, a mixture of a-tubulin peptide substrate (residues 36–44, H-PSDK
(Acetyl)TIGGWW-NH2, 2.5–75 mM, for details about the a-tubulin peptide
synthesis see Supplementary Methods), b-NADþ (5–1,500 mM), SirReal1/2
(various concentrations in 50mM Tris/HCl, 137mM NaCl, 2.7mM KCl, 1mM
MgCl2, 5% (v/v) DMSO, pH 8.0) was incubated (37 C). The reaction was started
by the addition of human Sirt256–356 (2mM), stopped after 1–50min with TFA
(10% (v/v), ﬁnal concentration 1% (v/v)) and analysed by HPLC as described
above. The peak areas were integrated and converted to initial velocities calculated
from the peak areas as the fraction of deacetylated peptide from total peptide. From
this, reaction rates in mM min 1 were obtained by linear regression, while Km and
kcat were obtained directly from Michaelis–Menten plots using Graphpad Prism
software. b-NADþ (500 mM) was used for the determination of the kinetic
parameters for the peptide substrate, 100 mM of peptide substrate was used for the
determination of the kinetic parameters for b-NADþ .
Thermal shift assays. Human Sirt256–356 (0.2mgml 1 ﬁnal concentration) was
mixed with or without ligand containing buffer (25mM Tris/HCl, 150mM NaCl,
5% (v/v) DMSO, 1:4,000 Sypro Orange, pH 8.0) in absence or presence of
b-NADþ (100mM stock solution in 25mM Tris/HCl, 150mM NaCl, pH 8.0, ﬁnal
assay concentration 5mM) or acetylated H3-peptide (100mM stock solution in
25mM HEPES, 200mM NaCl, 5% (v/v) glycerol, pH 7.5, ﬁnal assay concentration
5mM). Fluorescence was monitored during a temperature ramp from 25–95 C
(1 Cmin 1) using a Bio-Rad iCycler iQ5 (4titude, FrameStar 96-well plates,
4ti-0771, 4titude qPCR Seal, 4ti-0560). Melting temperatures were determined
according to published procedures68 using Graphpad Prism software.
Cell cultivation. HeLa cells (DSMZ accession no. 057) and U2OS cells (ATCC
accession no. HTB-96) were grown in Dulbecco’s modiﬁed Eagle’s medium (PAA)
containing 10% (v/v) fetal calf serum (FCS, PAA), 1% (v/v) penicillin (PAA), 1%
(v/v) streptomycin (PAA), 1% (v/v), L-glutamine (PAA) at 37 C in a 5% (v/v) CO2
atmosphere.
Tubulin acetylation. HeLa cells were plated in petri dishes (5 cm, PAA), incubated
overnight to a conﬂuency of 30–40% and then treated with SirReal2 dissolved in
RPMI1640 medium supplemented with fresh 20% (v/v) FCS (PAA), 1% (v/v)
penicillin (PAA), 1% (v/v) streptomycin (PAA), 1% (v/v), L-glutamine (PAA),
1% (v/v) DMSO for 5 h at various concentrations. Cells were then washed with
prewarmed PBS (2ml), lysed in SDS–PAGE sample buffer (70 ml, 50mM Tris/HCl,
0.5mM EDTA, 1 Complete Protease Inhibitors (Sigma-Aldrich), 2% (v/v)
IGEPAL (Sigma-Aldrich), 2% (w/v) SDS, 10% (v/v) glycerol, 50mM NCA
(Sigma-Aldrich), 3.3 mM trichostatin A (Sigma-Aldrich), 50mM DTT, 0.01% (w/v)
bromophenol blue, pH 6.8) and sonicated (5min). Cell samples were then
separated using SDS–PAGE (12.5% (w/v) polyacrylamide), transferred to an
activated nitrocellulose membrane (Bio-Rad), blocked with non-fat dry milk
(Roth, 5% (w/v), TBS, 0.1% (v/v) Tween 20) and probed with an anti-acetyl-a-
tubulin antibody (1:1,000, Sigma-Aldrich, T6793) and an anti-GAPDH antibody
(1:2,000–1:5,000, Sigma-Aldrich, G9545) as a loading control (Fusion SL, peqlab).
An uncropped blot is shown in Supplementary Fig. 8.
Abundance of BubR1. HeLa cells plated in six-well plates were treated with
SirReal2 dissolved in FCS (1% (v/v) DMSO, 16 h) at various concentrations. Cells
were washed with PBS, lysed in IPLS (50mM Tris/HCl, 150mM NaCl, 0.5mM
EDTA, 0.5% (v/v) NP-40, pH 7.5, supplemented with Complete protease inhibitors
(Roche)). Samples were pelleted and resuspended in 1 SDS–PAGE sample buffer
and heated (95 C, 5min). Cell samples were separated using SDS–PAGE (10%
(w/v) polyacrylamide), transferred to a nitrocellulose membrane (Bio-Rad),
blocked with non-fat dry milk (Roth, 5% (w/v), TBS, 0.1% (v/v) Tween 20) and
probed with the anti-BubR1 (1:5,000, BD Biosciences, 612502) and anti-tubulin
(1:5,000, Sigma-Aldrich, T5168) as a loading control. Uncropped blots are shown
in the Supplementary Fig. 8.
Immunocytochemistry. HeLa cells that were incubated with SirReal2 (20 and
50 mM), SirReal6 (50 mM), AGK2 (Sigma-Aldrich, 20 mM) or DMSO as a control in
Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% FCS, antibiotics and
DMSO (1% (v/v)) for 4 h, were ﬁxed with ice-cold methanol (10min), washed with
PBS and blocked with PBS supplemented with 0.1% (v/v) Triton-X-100 and 5%
(v/v) FCS (30min). Cells were then stained with an anti-acetyl-a-tubulin antibody
(Sigma-Aldrich, T6793) and then probed with a secondary Alexa 546
conjugated anti-mouse-antibody (Invitrogen). Nuclei were counterstained with
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DAPI (40 ,6-diamidino-2-phenylindole). Coverslips were mounted with Fluor-
oMount (Sigma-Aldrich) and sealed with DPX Mountant (Sigma-Aldrich). Images
of the mounted samples were acquired on a Leica DM500 microscope equipped
with a Leica DFC 395 FX camera and HBO 100W lamp40. The microscope was run
with the Leica Application Suite 4.4.0 software. Chroma UV ﬁlter set (No. C40888)
and Leica N2.1 ﬁlter set (No. 513832) were used for DAPI and Alexa 546 signal
acquisition, respectively, with a HCX FL Fluotar 40x/0.75 (dry) objective. Further
details about the equipment and the settings that were used to acquire the images
are found in the Supplementary Methods section. Unprocessed images are found in
Supplementary Fig. 9.
p53 Acetylation. U2OS cells (ATCC accession no. HTB-96) were seeded and
cultured until they reached 90% conﬂuency. Cells were then pretreated for 1 h with
NCA (Sigma-Aldrich), SirReal2, SirReal5 or SirReal6 at the indicated concentra-
tions, and then subsequently exposed to 20 J cm 2 ultraviolet light. Cells were
incubated for an additional 6 h in the presence of the inhibitor and then lysed in
IPLS (50mM Tris/HCl, 150mM NaCl; 0.5mM EDTA; 0.5% (v/v) NP-40; 1
Complete Protease Inhibitors (Roche), pH 8.0) and resuspended in 1 Laemmli
Buffer. Samples were then separated on SDS–PAGE, transferred to a nitrocellulose
membrane (Bio-Rad), blocked with non-fat dry milk (Roth, 5% (w/v), TBS, 0.1%
(v/v) Tween 20) and probed with anti-acetyl-p53 K382 (Cell Signaling, #2522),
anti-p53 DO.1 (Santa Cruz Biotechnology, sc-126) and anti-vinculin (Cell Sig-
naling, #4650) as a loading control. Uncropped blots are shown in the
Supplementary Fig. 10.
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